AMPH Amphastar Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AMPH

Price (delayed)

$18.855

Market cap

$831.37M

P/E Ratio

11.03

Dividend/share

N/A

EPS

$1.71

Enterprise value

$1.35B

?
Relative Growth: Rel. Growth: 51
Relative Strength: Rel. Strength: 15
Relative Valuation: Rel. Valuation: 82
Relative Profitability: Rel. Profitability: 55

Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active ...

Highlights
The stock's P/E is 47% less than its 5-year quarterly average of 19.9 and 2.8% less than its last 4 quarters average of 10.9
Amphastar Pharmaceuticals's quick ratio has increased by 39% YoY
The net income has contracted by 44% YoY and by 19% from the previous quarter
The EPS has contracted by 41% YoY and by 19% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.amphastar.com
Peers: SCYX

Key stats

What are the main financial stats of AMPH

AMPH stock price

How has the Amphastar Pharmaceuticals stock price performed over time
Intraday
4.06%
1 week
-2.31%
1 month
-17.08%
1 year
-27.09%
YTD
-29.59%
QTD
-3.75%

Financial performance

How have Amphastar Pharmaceuticals's revenue and profit performed over time
Revenue
$720.53M
Gross profit
$341.13M
Operating income
$116.74M
Net income
$79.23M
Gross margin
47.3%
Net margin
11%
The net income has contracted by 44% YoY and by 19% from the previous quarter
AMPH's net margin is down by 43% year-on-year and by 19% since the previous quarter
The operating income has declined by 40% year-on-year and by 17% since the previous quarter
AMPH's operating margin is down by 39% year-on-year and by 17% since the previous quarter

Price vs fundamentals

How does AMPH's price correlate with its fundamentals

Growth

What is Amphastar Pharmaceuticals's growth rate over time

Valuation

What is Amphastar Pharmaceuticals stock price valuation
AMPH P/E details
P/E
11.03
P/B
1.11
P/S
1.19
EV/EBIT
10.47
EV/EBITDA
6.98
EV/Sales
1.87
The stock's P/E is 47% less than its 5-year quarterly average of 19.9 and 2.8% less than its last 4 quarters average of 10.9
The EPS has contracted by 41% YoY and by 19% from the previous quarter
The price to book (P/B) is 61% lower than the 5-year quarterly average of 2.7 and 24% lower than the last 4 quarters average of 1.4
Amphastar Pharmaceuticals's equity has increased by 2.9% YoY
AMPH's price to sales (P/S) is 59% less than its 5-year quarterly average of 2.8 and 24% less than its last 4 quarters average of 1.5

Efficiency

How efficient is Amphastar Pharmaceuticals business performance
The ROE has contracted by 47% YoY and by 20% from the previous quarter
The company's return on assets fell by 47% YoY and by 20% QoQ
The ROIC is down by 41% year-on-year and by 15% since the previous quarter
The ROS has contracted by 35% YoY and by 14% from the previous quarter

Dividends

What is AMPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMPH.

Financial health

How did Amphastar Pharmaceuticals financials performed over time
The total assets is 88% greater than the total liabilities
Amphastar Pharmaceuticals's quick ratio has increased by 39% YoY
Amphastar Pharmaceuticals's current ratio has increased by 31% YoY but it has decreased by 4.2% from the previous quarter
AMPH's debt is 11% smaller than its equity
Amphastar Pharmaceuticals's debt to equity has increased by 7% from the previous quarter and by 2.3% YoY
AMPH's debt is up by 5% year-on-year and by 4.6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.